Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
18 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
26 Mar 24
8-K
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive
19 Mar 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
8-K
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
29 Feb 24
8-K
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
21 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
8 Jan 24
8-K
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
3 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Dec 23
8-K
Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
28 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
11 Mar 24
424B3
Prospectus supplement
24 Jan 24
S-3
Shelf registration
11 Jan 24
424B4
Prospectus supplement with pricing info
6 Dec 23
S-1/A
IPO registration (amended)
1 Dec 23
S-1
IPO registration
7 Nov 23
424B5
Prospectus supplement for primary offering
1 Sep 23
D/A
$12.78 mm in equity / options / securities to be acquired, sold $12.78 mm, 2 investors
19 Apr 23
S-8
Registration of securities for employees
20 Jan 23
424B3
Prospectus supplement
12 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
18 Sep 23
DEF 14A
Definitive proxy
18 Sep 23
PRE 14A
Preliminary proxy
7 Sep 23
DEF 14A
Definitive proxy
23 Sep 22
DEF 14A
Definitive proxy
31 May 22
PRE 14A
Preliminary proxy
20 May 22
DEF 14A
Definitive proxy
13 Apr 21
PRE 14A
Preliminary proxy
19 Mar 21
DEF 14A
Definitive proxy
4 Nov 20
DEFA14A
Additional proxy soliciting materials
30 Oct 19
Other
EFFECT
Notice of effectiveness
23 Jan 24
CORRESP
Correspondence with SEC
19 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
EFFECT
Notice of effectiveness
6 Dec 23
CORRESP
Correspondence with SEC
4 Dec 23
UPLOAD
Letter from SEC
16 Nov 23
UPLOAD
Letter from SEC
5 Jul 23
CORRESP
Correspondence with SEC
8 Jun 23
UPLOAD
Letter from SEC
15 May 23
EFFECT
Notice of effectiveness
12 Aug 22
Ownership
4
Joseph Edward Tucker
26 Feb 24
4
Peter J. Facchini
26 Feb 24
4
Kevin Michael Coveney
26 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
5 Feb 24
4
FRANK PASQUALONE
19 Sep 23
4
Kevin Michael Coveney
14 Mar 23
3
Kevin Michael Coveney
14 Mar 23
SC 13G
AdvisorShares Trust
14 Feb 23